CXCL8 and acute kidney injury: Jens Bedke’s team demonstrated that dnCXCL8, a novel antagonist derived from human C-X-C motif chemokine ligand 8 (CXCL8) with high GAGs-binding affinity but low C-X-C chemokine receptor type 1/2 activation capacity, significantly inhibits endothelium-dependent neutrophil infiltration in AKI.